Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comité de surveillance indépendant dans les essais cliniques : de la justification scientifique à l’organisation.
Locher C, Laporte S, Derambure P, Chassany O, Girault C, Avakiantz A, Bahans C, Deplanque D, Fustier P, Germe AF, Kassaï B, Lacoste L, Petitpain N, Roustit M, Simon T, Train C, Cucherat M. Locher C, et al. Among authors: fustier p. Therapie. 2024 Jan-Feb;79(1):99-110. doi: 10.1016/j.therap.2023.10.013. Epub 2023 Nov 3. Therapie. 2024. PMID: 37985309 Free article. French. No abstract available.
Data Monitoring Committees and clinical trials: From scientific justification to organisation.
Locher C, Laporte S, Derambure P, Chassany O, Girault C, Avakiantz A, Bahans C, Deplanque D, Fustier P, Germe AF, Kassaï B, Lacoste L, Petitpain N, Roustit M, Simon T, Train C, Cucherat M. Locher C, et al. Among authors: fustier p. Therapie. 2024 Jan-Feb;79(1):111-121. doi: 10.1016/j.therap.2023.12.002. Epub 2023 Dec 5. Therapie. 2024. PMID: 38103949 Free article.
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study.
Kingsley J, Kumarasamy N, Abrishamian L, Bonten M, Igbinadolor A, Mekebeb-Reuter M, Rosa J, Solai Elango D, Lopez P, Fustier P, Goncalves S, Knutson CG, Kukkaro P, Legenne P, Ramanathan K, Rao S, Reshetnyak E, Stavropoulou V, Stojcheva N, Stumpp MT, Tietz A, Soergel M, Chandra R. Kingsley J, et al. Among authors: fustier p. Open Forum Infect Dis. 2024 May 3;11(6):ofae233. doi: 10.1093/ofid/ofae233. eCollection 2024 Jun. Open Forum Infect Dis. 2024. PMID: 38854392 Free PMC article.
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.
Stojcheva N, Gladman S, Soergel M, Zitt C, Drake R, Lockett T, Marchand C, Fustier P, Stavropoulou V, Fernandez E, Pettigiani NL, Watkins K, Puri A, Watson R, Legenne P, Stumpp MT, Boyce M. Stojcheva N, et al. Among authors: fustier p. Br J Clin Pharmacol. 2023 Jul;89(7):2295-2303. doi: 10.1111/bcp.15747. Epub 2023 May 8. Br J Clin Pharmacol. 2023. PMID: 37057679 Free article. Clinical Trial.
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K. Izutsu K, et al. Among authors: fustier p. Int J Hematol. 2020 Mar;111(3):409-416. doi: 10.1007/s12185-019-02802-y. Epub 2019 Dec 19. Int J Hematol. 2020. PMID: 31858429 Clinical Trial.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. Leonard JP, et al. Among authors: fustier p. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. J Clin Oncol. 2019. PMID: 30897038 Free PMC article. Clinical Trial.
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. Czuczman MS, et al. Among authors: fustier p. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. doi: 10.1158/1078-0432.CCR-16-2818. Epub 2017 Apr 5. Clin Cancer Res. 2017. PMID: 28381416 Free PMC article. Clinical Trial.
27 results